{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:29:40Z","timestamp":1757705380142},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.diagmicrobio.2006.01.005","type":"journal-article","created":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T15:23:59Z","timestamp":1142004239000},"page":"157-164","source":"Crossref","is-referenced-by-count":15,"title":["Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998\u20132003)"],"prefix":"10.1016","volume":"55","author":[{"given":"Kelley A.","family":"Fedler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Fritsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.diagmicrobio.2004.08.017","article-title":"Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States","volume":"51","author":"Bhavnani","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jac\/dkf152","article-title":"Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance","volume":"50","author":"Boswell","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2006.01.005_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijantimicag.2003.09.006","article-title":"Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose","volume":"23","author":"Boy","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.46.3.680-688.2002","article-title":"Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994\u20131995","volume":"46","author":"Brueggemann","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1086\/516119","article-title":"Quinolone arthropathy in animal versus children","volume":"25","author":"Burkhardt","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.49.3.1106-1112.2005","article-title":"Pharmacokinetics of gatifloxacin in infants and children","volume":"49","author":"Capparelli","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib8","series-title":"Performance standard for antimicrobial susceptibility testing, 15th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2005"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/jac\/33.4.685","article-title":"Structure\u2013activity and structure\u2013side-effect relationships for the quinolone antibacterials","volume":"33","author":"Domagala","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/498318","article-title":"Gatifloxacin therapy for children: turn on the light","volume":"41","author":"Echols","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib10","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1128\/AAC.42.9.2459","article-title":"Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms","volume":"42","author":"Ednie","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2958.1994.tb00458.x","article-title":"Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones","volume":"13","author":"Ferrero","year":"1994","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/45.4.437","article-title":"In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin","volume":"45","author":"Fung-Tomc","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.inf.0000101994.25947.12","article-title":"Safety profile of quinolone antibiotics in the pediatric population","volume":"22","author":"Grady","year":"2003","journal-title":"Pediatr. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.diagmicrobio.2006.01.005_bib14","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/314061","article-title":"Clinical pharmacology of gatifloxacin, a new fluoroquinolone","volume":"31","author":"Grasela","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.43.6.1475","article-title":"Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections","volume":"43","author":"Goldstein","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib16","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.40.12.2760","article-title":"High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA","volume":"40","author":"Janoir","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib17","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1128\/JCM.38.11.4298-4299.2000","article-title":"Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997\u20131999)","volume":"38","author":"Jones","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0732-8893(03)00015-4","article-title":"Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (200\u20132001): report from the SENTRY Antimicrobial Surveillance Program","volume":"46","author":"Jones","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/367935","article-title":"The role of clonality in the global spread of fluoroquinolones-resistant bacteria","volume":"36","author":"Klugman","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1086\/341900","article-title":"The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?","volume":"35","author":"Mandell","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.39.12.2635","article-title":"Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans","volume":"39","author":"Nakashima","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib22","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6","author":"National Committee for Clinical Laboratory Standards","year":"2003"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib32","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1086\/431584","article-title":"Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and\/or AOM treatment failure","volume":"41","author":"Pichichero","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00006454-199905000-00015","article-title":"Pediatric use of quinolones","volume":"18","author":"Schaad","year":"1999","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0301-2115(95)02524-3","article-title":"Pregnancy outcome after prenatal quinolone exposure evaluation of a case registry of the European Network of Teratology Information Services (ENTIS)","volume":"69","author":"Schaefer","year":"1996","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s002040050009","article-title":"Chondrotoxicity of ciprofloxacin in immature beagle dogs: immunohistochemistry, electron microscopy and drug plasma concentrations","volume":"73","author":"Stahlmann","year":"2000","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1191\/096032799678840237","article-title":"The comparative arthropathy of fluoroquinolones in dogs","volume":"18","author":"Takizawa","year":"1999","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib27","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1128\/AAC.45.8.2358-2362.2001","article-title":"Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double blind, multicenter, randomized study","volume":"45","author":"Tarshis","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijantimicag.2005.06.017","article-title":"Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones","volume":"26","author":"Wogelius","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib29","doi-asserted-by":"crossref","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","article-title":"DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance","volume":"94","author":"Zhao","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.diagmicrobio.2006.01.005_bib30","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.42.4.956","article-title":"Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones","volume":"42","author":"Zhao","year":"1998","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889306000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889306000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T04:03:43Z","timestamp":1586750623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889306000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0732889306000071"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2006.01.005","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}